Related Experiment Videos
Liposome-mediated peptide loading of MHC-DR molecules in vivo
B A t Hart1, D G Elferink, J W Drijfhout
1Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands. hart@bprc.nl
Abstract:
Amino acid residues 3-15 of mycobacterial HSP60 define a dominant T-cell epitope for HLA-DR3+ve humans and Mamu-DR3+ve rhesus monkeys. Our results show that Mamu-DR3 molecules on PBMC can be efficiently loaded in vivo with the above-mentioned peptides when they are intravenously injected encapsulated in liposomes, but not in the free form. Mamu-DR3 loading is abolished by encapsulation of a nonstimulatory peptide. These results have implications for the delivery of therapeutic peptides in vivo.
Insights
Liposome encapsulation enhances in vivo delivery of mycobacterial HSP60 peptides to Mamu-DR3 molecules in rhesus monkeys. This method improves peptide loading for potential therapeutic applications.
Area of Science:
- Immunology
- Biotechnology
- Drug Delivery
Background:
- Mycobacterial Heat Shock Protein 60 (HSP60) contains T-cell epitopes.
- Specific epitopes are recognized by HLA-DR3 in humans and Mamu-DR3 in rhesus monkeys.
Purpose of the Study:
- To investigate the in vivo loading of Mamu-DR3 molecules with HSP60-derived peptides.
- To evaluate the efficacy of liposome encapsulation for peptide delivery.
Main Methods:
- Intravenous injection of liposome-encapsulated peptides in Mamu-DR3+ve rhesus monkeys.
- Comparison with free peptide administration.
- Assessment of Mamu-DR3 loading using non-stimulatory peptides for control.
Main Results:
- Liposome encapsulation significantly enhanced in vivo loading of HSP60 peptides into Mamu-DR3 molecules on peripheral blood mononuclear cells (PBMC).
- Free peptide administration resulted in inefficient loading.
- Encapsulation of a non-stimulatory peptide blocked Mamu-DR3 loading, confirming specificity.
Conclusions:
- Liposomes are an effective delivery vehicle for enhancing in vivo peptide loading onto Mamu-DR3 molecules.
- This approach holds promise for the development of novel peptide-based therapies.